Breast
Phase III study evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
GBG 1115 | 15-1373
View full trial information.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Esophageal
A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel
HCP 2215 | 031520C
View full trial information.
Pancreas
A Phase II Study of Second-Line Therapy with Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
CASE 5214 | 15-166
View full trial information.
Renal
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (Msb0010718c) In Combination With Axitinib (Inlyta®) Versus Sunitinib (Sutent®) Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma
PFIZ 2816 | 16-573
View full trial information.
Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors
GITR 1Y15 | 101506C
View full trial information.
Myelodysplastic Syndrome (MDS)
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo For the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions
CLGN 2915 | 16-462
View full trial information.
Lymphoma, Diffuse Large B Cell
A Phase I/II Study of Carfilzomib in Combination with R-CHOP (CR-CHOP) for Patients with Diffuse Large B -Cell Lymphoma
CASE 3413 | 14-256
View full trial information.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
